Uneingeschränkter Zugang

The Evaluation of Cardiovascular Risk in Diabetic Patients

S. Kosirova

S. Kosirova

Comenius University Bratislava, Faculty of PharmacyBratislava, SLOVAKIA
Suche nach diesem Autor auf
Sciendo|Google Scholar
Kosirova, S.
, 
D. Rubintova

D. Rubintova

Trnava, Slovakia
Suche nach diesem Autor auf
Sciendo|Google Scholar
Rubintova, D.
, 
J. Lacka

J. Lacka

Trnava, Slovakia
Suche nach diesem Autor auf
Sciendo|Google Scholar
Lacka, J.
, 
J. Klimas

J. Klimas

Comenius University Bratislava, Faculty of PharmacyBratislava, SLOVAKIA
Suche nach diesem Autor auf
Sciendo|Google Scholar
Klimas, J.
, 
T. Foltanova

T. Foltanova

Comenius University Bratislava, Faculty of PharmacyBratislava, SLOVAKIA
Suche nach diesem Autor auf
Sciendo|Google Scholar
Foltanova, T.
 und 
I. Tumova

I. Tumova

Comenius University Bratislava, Faculty of PharmacyBratislava, SLOVAKIA
Suche nach diesem Autor auf
Sciendo|Google Scholar
Tumova, I.
  
04. Apr. 2022
The Evaluation of Cardiovascular Risk in Diabetic Patients's Cover Image
Über diesen Artikel
Vorheriger Artikel
Nächster Artikel
Zitieren
COVER HERUNTERLADEN
Artikel-Kategorie: Original Paper
Online veröffentlicht: 04. Apr. 2022
Seitenbereich: 1 - 8
Eingereicht: 06. Aug. 2021
Akzeptiert: 05. Nov. 2021
DOI: https://doi.org/10.2478/afpuc-2022-0001
Schlüsselwörter
© 2022 S. Kosirova et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Figure 1

The distribution of patients according to HbA1c levels at the baseline and at the end of the study. V1 – visit 1 (baseline), V2 – visit 2 (the end of the study).
The distribution of patients according to HbA1c levels at the baseline and at the end of the study. V1 – visit 1 (baseline), V2 – visit 2 (the end of the study).

Figure 2

The distribution of patients according to the cardiovascular risk in men and women. V1 – visit 1 (baseline), V2 – visit 2 (the end of the study), CHD – coronary heart disease.
The distribution of patients according to the cardiovascular risk in men and women. V1 – visit 1 (baseline), V2 – visit 2 (the end of the study), CHD – coronary heart disease.

Figure 3

The cardiovascular risk according UKPDS risk engine in men and women. Values represents mean ± standard error of the mean. **p<0.01, ***p<0.001 vs. women, CHD – coronary heart disease.
The cardiovascular risk according UKPDS risk engine in men and women. Values represents mean ± standard error of the mean. **p<0.01, ***p<0.001 vs. women, CHD – coronary heart disease.

The cardiovascular risk according to UKPDS risk engine in men and women_

CVD risk Women mean (%) ± SEM (min.–max. %) Men mean (%) ± SEM (min.–max. %) M vs. W p <
V1 CHD 16.58 ± 0.89 (3.10–54.90) 30.61 ± 1.87 (4.10–75.80) 0.001
V2 CHD 17.17 ± 1.03 (1.40–63.60) 30.94 ± 1.75 (5.00–70.90) 0.001
V1 fatal CHD 12.49 ± 0.84 (1.50–49.30) 23.33 ± 1.76 (1.10–66.50) 0.001
V2 fatal CHD 13.38 ± 0.98 (0.50–60.50) 24.05 ± 1.70 (1.50–65.70) 0.001
V1 stroke 9.76 ± 0.88 (1.00–55.80) 15.99 ± 1.94 (0.90–89.20) 0.01
V2 stroke 11.91 ± 1.00 (1.10–58.60) 19.23 ± 2.07 (0.80–92.90) 0.01
V1 fatal stroke 1.71 ± 0.17 (0.20–10.30) 2.98 ± 0.41 (0.10–21.40) 0.01
V2 fatal stroke 2.00 ± 0.19 (0.10–11.30) 3.44 ± 0.38 (0.10–16.80) 0.01
Sprache:
Englisch
Zeitrahmen der Veröffentlichung:
2 Hefte pro Jahr
Fachgebiete der Zeitschrift:
Pharmazie, Pharmazie, andere
Zeitschrift RSS Feed